The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: Reconstitution of skin fibrosis development using a tissue engineering approach

Journal of Pathology

Volumn 217, Issue 4, 2009, Pages 534-542

  Corriveau, Marie Pier ^a   Boufaied, Inès ^a   Lessard, Julie ^a   Chabaud, Stéphane ^a   Senécal, Jean Luc ^b,c   Grodzicky, Tamara ^b,c   Chartier, Suzanne ^b,c   Raymond, Yves ^b,c   Moulin, Veronique J ^a,d  

^a LAVAL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Extracellular matrix; Fibrosis; Systemic sclerosis; TGF ; Tissue engineering

Indexed keywords

COLLAGEN TYPE 1; COLLAGENASE; CONNECTIVE TISSUE GROWTH FACTOR; INTERSTITIAL COLLAGENASE; TRANSFORMING GROWTH FACTOR BETA1; CTGF PROTEIN, HUMAN; MATRIX METALLOPROTEINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL GROWTH; CELL ISOLATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DERMIS; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FIBRIN FORMATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; SKIN FIBROBLAST; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TISSUE ENGINEERING; CASE CONTROL STUDY; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECT; FIBROBLAST; FIBROSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SECRETION; SKIN;

ADULT; AGED; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASES; MIDDLE AGED; PHENOTYPE; SCLERODERMA, SYSTEMIC; SKIN; TISSUE ENGINEERING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 62849086209     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2482     Document Type: Article

References (30)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
2. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006;54:1961-1973.
3. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-12324.
4. Zurita-Salinas CS, Krotzsch E, Diaz de Leon L, Alcocer-Varela J. Collagen turnover is diminished by different clones of skin fibroblasts from earlybut not late-stage systemic sclerosis. Rheumatol Int 2004;24:283-290.
5. Kikuchi K, Hartl CW, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: insensitivity to TGF beta 1 stimulation. Biochem Biophys Res Commun 1992;187:45-50.
6. Bellemare J, Roberge CJ, Bergeron D, Lopez-Valle CA, Roy M, Moulin VJ. Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scar. J Pathol 2005;206:1-8.
7. Needleman BW, Choi J, Burrows-Mezu A, Fontana JA. Secretion and binding of transforming growth factor beta by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990;33:650-656.
8. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:567-572.
9. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61:239-246.
10. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localiza tion of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-1276.
11. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005;52:865-876.
12. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81:154-167.
13. Robitaille G, Henault J, Christin MS, Senecal JL, Raymond Y. The nuclear autoantigen CENP-B displays cytokine-like activ ities toward vascular smooth muscle cells. Arthritis Rheum 2007;56:3814-3826.
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-590.
15. Steen VD, Medsger TA Jr, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652-659.
16. Moulin V, Plamondon M. Differential expression of collagen integrin receptor on human fetal versus adult skin fibroblasts: implication in wound contraction during healing. Br J Dermatol 2002;147:886-892.
17. Vermette M, Trottier V, Menard V, Saint-Pierre L, Roy A, Fradette J. Production of a new tissue-engineered adipose substitute from human adipose-derived stromal cells. Biomaterials 2007;28:2850-2860.
18. Singer VL, Jones LJ, Yue ST, Haugland RP. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem 1997;249:228-238.
19. Scherrer B. Biostatistique. G Morin: Montreal, 1984.
20. Pietramaggiori G, Liu P, Scherer SS, Kaipainen A, Prsa MJ, Mayer H, et al. Tensile forces stimulate vascular remodeling and epidermal cell proliferation in living skin. Ann Surg 2007;246:896-902.
21. Postiglione L, Montagnani S, Riccio A, Montuori N, Sciorio S, Ladogana P, et al. Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol 2002;29:94-101.
22. Wang Y, Fan P-S, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006;54:2271-2279.
23. Kono T, Tanii T, Furukawa M, Mizuno N, Kitajima J, Ishii M, et al. Cell cycle analysis of human dermal fibroblasts cultured on or in hydrated type I collagen lattices. Arch Dermatol Res 1990;282:258-262.
24. Kuroda K, Shinkai H. Decorin and glycosaminoglycan synthesis in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:481-485.
25. Wallis DD, Tan FK, Kielty CM, Kimball MD, Arnett FC, Milewicz DM. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001;44:1855-1864.
26. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008;34:115-143;vii.
27. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-146.
28. Gore-Hyer E, Pannu J, Smith EA, Grotendorst G, Trojanowska M. Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum 2003;48:798-806.
29. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP- lbeta) in patients with systemic sclerosis: MCP-1 and MIP-lalpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-165.
30. Selvi E, Tripodi SA, Catenaccio M, Lorenzini S, Chindamo D, Manganelli S, et al. Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis 2003;62:460-464.